Loading...
•
Sep 30, 2023
Nektar Q3 2023 Earnings Report
Reported financial results for the third quarter ended September 30, 2023.
Key Takeaways
Nektar Therapeutics reported revenue of $24.1 million and a net loss of $45.8 million for the third quarter of 2023. The company's cash and investments in marketable securities were $372.7 million as of September 30, 2023, expected to support operations into mid-2026.
Initiated a Phase 2b atopic dermatitis study in October.
Completing plans to start a Phase 2b alopecia areata study in early 2024.
Signed a new clinical study collaboration with Cellular Biomedicine Group to evaluate NKTR-255 in combination with CBMG’s tumor-infiltrating lymphocyte therapy in advanced non-small cell lung cancer.
Ended the quarter with at least $320 million in cash and investments, providing a cash runway into the middle of 2026.
Forward Guidance
Nektar expects to end the year in a strong financial position with at least $320 million in cash and investments, which provides a cash runway into the middle of 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...